New system distinguishes suspicious pigmented lesions from non-suspicious ones
Melanoma is by far the deadliest form of skin cancer, killing more than 7,000 people in the United States in 2019 alone. Early detection of the disease dramatically reduces the risk of death and the costs of treatment, but widespread melanoma screening is not currently feasible. There are about 12,000 practicing dermatologists in the US, and they would each need to see 27,416 patients per year to screen the entire population for suspicious pigmented lesions (SPLs) that can indicate cancer.
Computer-aided diagnosis (CAD) systems have been developed in recent years to try to solve this problem by analyzing images of skin lesions and automatically identifying SPLs, but so far have failed to meaningfully impact melanoma diagnosis.
Share this article
Share this article
BOSTON, Feb. 17, 2021 /PRNewswire/ The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with GBS’s transistor technology in developing a multiplexed COVID-19 biomarker diagnostic. Credit: Wyss Institute at Harvard University
E-Mail
IMAGE: The Wyss Institute collaborates with GBS Inc., a subsidiary of The iQ Group Global, to combine its electrochemical eRapid sensing technology with the GBS s transistor technology in developing a multiplexed. view more
Credit: Wyss Institute at Harvard University
(BOSTON) The Wyss Institute for Biologically Inspired Engineering at Harvard University and GBS Inc., a subsidiary of The iQ Group Global, announce that they will collaborate to validate and de-risk a specific and sensitive COVID-19 diagnostic that would integrate the Institute s eRapid technology with the company s proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.
DIMMING THE SUN: Bill Gates and other Family Office Owners Allocate Capital to Solar Geoengineering
Posted on 02/17/2021
The Paris Agreement is an agreement within the United Nations Framework Convention on Climate Change, on climate change mitigation, adaptation, and finance, signed in 2016. There are many attempts and experiments trying to control global warming. Solar geoengineering refers to proposed approaches to cool the Earth by reflecting solar radiation back to space. Some of these experimental ideas range from sending a giant mirror into space to spraying aerosols in the stratosphere. The two main approaches being researched are stratospheric aerosol injection (SAI) and marine cloud brightening (MCB). Microsoft’s billionaire founder Bill Gates is financially backing the development of technology that could dim the sun. The Stratospheric Controlled Perturbation Experiment (SCoPEx) was launched by Harvard University scientists. The goal of the experiment is to examine thi
Harvard s Wyss Institute collaborates with GBS Inc on the Wyss eRapid-based COVID-19 diagnostic to help curb the pandemic apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.